Mode
Text Size
Log in / Sign up

Cryptogenic cerebral palsy cases show 2.21 risk ratio of pathogenic genomic findings compared to non-cryptogenicGenomic Testing Reveals Genetic Cause in 1 in 8 Cerebral Palsy Cases

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that cryptogenic cerebral palsy patients show a significantly higher frequency of pathogenic genomic findings than non-cryptogenic cases.

This meta-analysis evaluates the frequency of pathogenic or likely pathogenic (P/LP) genomic findings across different cerebral palsy (CP) phenotypes. The study included 1,885 individuals in the primary non-cryptogenic analysis and data from 7 studies regarding cryptogenic CP cohorts. Genomic sequencing methods included whole-exome, whole-genome, and targeted next-generation panels.

The meta-analysis found a 12.6% frequency of P/LP findings in non-cryptogenic CP (95% CI 8.9 to 17.6) and a significantly higher 32.3% frequency in cryptogenic CP (95% CI 21.0 to 46.1). The risk ratio for P/LP findings in cryptogenic versus non-cryptogenic cases was 2.21 (95% CI 1.56 to 3.14). The overall pooled frequency of P/LP findings across all cohorts was 19% (95% CI 12 to 28).

Limitations include heterogeneous definitions of non-cryptogenic CP and incomplete genotype-phenotype adjudication across the included studies. Clinicians should consider these results as a basis for careful assessment of perinatal risk factors, neuroimaging patterns, and genotype-phenotype concordance when interpreting genomic results in patients with cerebral palsy.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the genetic landscape of different cerebral palsy phenotypes. While previous evidence has explored non-pharmacological interventions such as transcranial magnetic stimulation for motor overflow and dual-task training for mobility, this study focuses on the underlying genomic architecture. Specifically, it highlights that cryptogenic cases have a higher risk ratio of 2.21 for pathogenic findings compared to non-cryptogenic cases.

A new meta-analysis of 1,885 individuals with cerebral palsy (CP) shows that genomic sequencing can identify a genetic cause in a significant number of cases. The study, which combined data from multiple research groups, found that 12.6% of people with non-cryptogenic CP (where a cause is not obvious) had a pathogenic or likely pathogenic genetic finding. For those with cryptogenic CP (no clear cause), the rate was even higher at 32.3%.

The analysis included people with both non-cryptogenic and cryptogenic CP. Researchers looked at results from whole-exome, whole-genome, and targeted next-generation sequencing. They found that the risk of having a genetic finding was about 2.2 times higher in cryptogenic cases compared to non-cryptogenic cases.

Overall, across all groups, about 19% of people with CP had a genetic finding. The study also noted that certain genes, like COL4A1 and COL4A2, were more common in specific CP types. However, the researchers caution that definitions of non-cryptogenic CP varied across studies, and not all genetic findings were fully verified.

This research suggests that genomic testing can help uncover the cause of CP in many cases, especially when the cause is not clear. But the results should be interpreted carefully, considering each person's medical history and brain imaging. No direct cause-and-effect was proven for specific genetic variants in this analysis.

What this means for you:
Genomic testing finds a genetic cause in about 1 in 8 people with cerebral palsy, and 1 in 3 when the cause is unknown.

Common questions

What does this study tell us about the cause of cerebral palsy?

It shows that genetic factors may play a role in many cases. In people with no clear cause, about 32% had a genetic finding. In those with other known risk factors, about 13% had a genetic finding.

Who was included in this study?

The study included 1,885 people with cerebral palsy from multiple research studies. It looked at both non-cryptogenic CP (where a cause is not obvious) and cryptogenic CP (no clear cause).

How reliable are these results?

The results are based on a meta-analysis, which combines data from several studies. However, definitions of non-cryptogenic CP varied across studies, and not all genetic findings were fully verified, so results should be interpreted with caution.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BackgroundThe contribution of genomic variants to non-cryptogenic cerebral palsy (CP), defined by identifiable perinatal or acquired risk factors, remains incompletely characterized. This study aimed to estimate the frequency of reported pathogenic or likely pathogenic (P/LP) genomic findings in non-cryptogenic CP and compare it with cryptogenic cohorts.MethodsWe conducted a systematic review and meta-analysis searching PubMed and Scopus to May 30, 2026, for sequencing-based CP studies with extractable non-cryptogenic data. Eligible approaches included whole-exome sequencing, whole-genome sequencing, and targeted next-generation sequencing panels. Risk of bias was assessed using an adapted JBI prevalence checklist. Pooled frequencies were calculated using random-effects models with logit transformation.ResultsEleven studies were included in the qualitative synthesis, and eight contributed to the meta-analysis. The primary non-cryptogenic analysis included 1,885 individuals, of whom 325 had reported P/LP genomic findings. The pooled frequency was 12.6% (95% CI 8.9–17.6; I2 = 80.6%), approximately one in eight tested individuals. In seven studies with cryptogenic subgroup data, the pooled frequency was 32.3% (95% CI 21.0–46.1; I2 = 69.9%). Cryptogenic cases were more than twice as likely to have a reported P/LP genomic finding as non-cryptogenic cases (risk ratio 2.21, 95% CI 1.56–3.14). Across all analyzed cohorts, the overall pooled frequency was 19% (95% CI 12–28). Prematurity was generally associated with lower frequencies, whereas selected hemorrhagic or cerebrovascular phenotypes showed enrichment for COL4A1/COL4A2-related findings.InterpretationReported P/LP genomic findings occur in a clinically meaningful subset of individuals with non-cryptogenic CP, although less frequently than in cryptogenic CP. Interpretation is limited by heterogeneous definitions of non-cryptogenic CP and incomplete genotype–phenotype adjudication across studies. These findings support careful assessment of perinatal risk factors, neuroimaging patterns, and genotype–phenotype concordance when interpreting genomic results.Systematic review registrationCRD420251169588, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251169588.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.